Please add the following new claims:

--69. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:

A) DNA comprising the sequence:

AGT GTG TGT CC CAA GGA AAA TAT **GAT** ATC CAC CCT CAA AAT TCG ATT TGC ACC AAG TGC CAC AAA GGA ACC TAC 7GT TTG TAC AAT **GAC TGT** CCA GGC CCG GGG CAG GAT ACG GAC **TGC** GGC TCC TTC AGG GAG TGT GAG AGC ACC GCT TCA GAA AAC CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG CTC AGA CAC GGT CAG GTG GAG ATO TCT TCT TGC ACA GTG GAC CGG GAC ACC CGG CAT GTG TGT GGC TGC AGG AAG AAC CAG TAC TAT TGG AGT CAG TGC AAT TGC AGC CTC GAA AAC CTT TTC TTC TGC CTC AAT GGG ACC GTG CAC C/TC TCC TGC CAG GAG AAA CAG AAC ACC **GTG** TGC ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC **GAG TGT** TGT AGT AAC AAG AAA AGC CTG GAG TGC ACG AAG **TCC TGT GTC** TTG TGC CTA CCC /CAG ATT GAG AAT

, or a C- and/or N-terminally shortened sequence thereof, wherein R² is absent or is a DNA comprising a sequence coding for a polypeptide which can be cleaved *in vivo*; and

B) DNA comprising the sequence:

R² GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA
AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC
TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC
AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC
CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG
GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC
GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT
GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT
GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG
TGC ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT
GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG
TTG TGC CTA CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC
TCA GGC ACC ACA

, or a C- and/or N- terminally shortened sequence thereof, wherein R² is absent or represents DNA coding for a polypeptide which can be cleaved *in vivo*.

70. Polypeptide according to claim 69, wherein R² is a DNA comprising a sequence which codes for a polypeptide which can be cleaved *in vivo*.

71. Polypeptide according to claim 69, wherein R² is a DNA comprising the sequence: CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA, or a C- and/or N- terminally shortened sequence thereof.

Polypeptide according to claim 69, wherein R² is a DNA encoding an amino acid sequence comprising: leu val pro his leu gly asp arg glu lys arg, or a C- and/or N- terminally shortened sequence thereof.

73. Polypeptide according to claim 70, wherein R² is a DNA comprising the sequence: R³ CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA, or a C- and/or N- terminally shortened sequence thereof, wherein R³ is a DNA coding for a signal peptide.

Polypeptide according to claim 10° , wherein 10° is a DNA encoding an amino acid sequence comprising: 10° leu val pro his leu gly asp arg glu lys arg, or a C- and/or N-terminally shortened sequence thereof, wherein 10° is a DNA coding for a signal peptide.

78. Polypeptide according to claim 73, wherein R³ is a DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CCA CTG GTG CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT GGA

; or/a C- and/or N- terminally shortened sequence thereof.

76. Polypeptide according to claim 73, wherein R³ is a DNA encoding an amino acid sequence comprising:

pro met gly leu ser thr val pro asp leu leu leu leu val glu leu leu gly ile tyr ser gly val ile leu val pro gly

; or a C- and/or N- terminally shortened sequence thereof.

- 3 -

É

- 77. Polypeptide according to claim 69, wherein said polypeptide is not associated with human urinary proteins.
- 78. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:
 - A) DNA comprising the sequence:

CTG GTC CCT CAC/CTA GGG GAC AGG GAG AAG AGA GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC CAC CTC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

B) DNA/comprising the sequence:

CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC
ACA

Cont.

, or a C- and/or N- terminally shortened sequence thereof;

C) DNA comprising the sequence:

GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT

, or a C- and/or N- term/nally shortened sequence thereof; and

D) DNA comprising/the sequence:

GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC
ACA

, or a C- and/or N- terminally shortened sequence thereof.

79. Polypeptide according to claim 78, wherein said polypeptide is not associated with human urinary proteins.



80. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:

A) DNA comprising the sequence:

ATG CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

B) DNA comprising the sequence:

ATG CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA ACC CAG AAT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC ACC

, or a C- and/or N- terminally shortened sequence thereof;



ري الجهي C) DNA comprising the sequence:

GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC TGC AGG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA CCC CAG ATT GAG AAA

, or a C- and/or N- terminally shortened sequence thereof;

D) DNA comprising the sequence:

ATG GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC
ACA

or a C- and/or N- terminally shortened sequence thereof;

E) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA CTG GTG CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT GGA CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG



ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAC TAC CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA CCC CAG ATT GAG AAT

, or a C- and/or N- te/minally shortened sequence thereof;

F) DNA comprising the sequence:

ATG GGC CTC /TCC ACC GTG CCT GAC CTG CTG CCA CTG GTG CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT GGA CTG GT¢ CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT C/CA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC/TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG CAC CT/C TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC ACA

, or \$\alpha\$ C- and/or N- terminally shortened sequence thereof;

G)/ DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CCA CTG GTG CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT GGA GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA



AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC TGC AGG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGC CTA ACC GTG TAC CTG GAG TGC ACG AAG TTG TGC CTA CCC CAG ATT GAG AAA

, or a C- and/or N- terminally shortened sequence thereof;

H) DNA comprising the sequence:

, or a $\not \mathbb{C}$ - and/or N- terminally shortened sequence thereof; and

I) /DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA CTG GTG CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT GGA CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT

GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG /TAC CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC TTC AAT/TGC AGC CTC TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC ACA GTG CTG TTG CCC CTG GTC ATT TTC TTT GGT CTT TGC CTT TTA TCC CTC CTC/TTC ATT GGT TTA ATG TAT CGC TAC CAA CGG TGG AAG TCC AAG CTC TAC TCC ATT GTT TGT GGG AAA TCG ACA CCT GAA AAA GAG GGG GAG CTT GAA GGA ACT ACT ACT AAG CCC CTG GCC CCA AAC CCA AGC TTC AGT CCC ACT CCA GGC TTC ACC CCC ACC CTG GGC TTC AGT CCC GTG CCC AGT TCC ACC TTC ACC TCC AGC TCC ACC TAT ACC CCC GGT GAC TGT CCC AAC TTT GCG GCT CCC CGC AGA GAG GTG GCA CCA CCC TAT CAG GGG GCT GAC CCC ATC CTT /GCG ACA GCC CTC GCC TCC GAC CCC ATC CCC AAC CCC CTT CAG/ AAG TGG GAG GAC AGC GCC CAC AAG CCA CAG AGC CTA GAC ACT/ GAT GAC CCC GCG ACG CTG TAC GCC GTG GTG GAG AAC GTG CC¢ CCG TTG CGC TGG AAG GAA TTC GTG CGG CGC CTA GGG CTG AGC GAC CAC GAG ATC GAT CGG CTG GAG CTG CAG AAC GGG CGC TGC CTG CGC GAG GCG CAA TAC AGC ATG CTG GCG ACC TGG AGG CGG CGC ACG CCG CGG CGC GAG GCC ACG CTG GAG CTG CTG GGA CGC GTG CTC CGC GAC ATG GAC CTG CTG GGC TGC CTG GAG GAC ATC GAG GAG GCG CTT TGC GGC CCC GCC GCC CTC CCG CCC GCG ¢CC AGT CTT CTC AGA

, or a C- and/or N- terminally shortened sequence thereof.

81. Polypeptide according to claim 80, wherein said polypeptide is not associated with human urinary proteins.

82. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, characterized in that the polypeptide is encoded by a nucleic acid which hybridizes with DNA complementary to the DNA defined in claim 69 under conditions of moderate stringency.

E

- 83. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is selected from the group consisting of:
 - A) a polypeptide compr/sing the amino acid sequence:

R² asp pro ser val cys gln gly lvs tvr ile his gln pro asn asn ser ile cys /cys thr lys cys his lys gly thr tyr leu cys gly thr tyr asn asp pro gly pro gln asp asp Cys arg glu glu ser ser phe thr ala ser glu asn his leu cys gly his leu/ ser lys lys qlu cys cys ser cys arg met gly arg gln glu ile/ ser ser thr val asp arg asp thr val val Cys a/g arg cys lys asn gln tyr his tyr trp cys gly ser glu asn léu phe gln cys phe asn cys ser leu cys leu thr val his leu gln glu lys gln asn thr asn gly ser cys thr his phe leu glu asn glu val cys cys ala gly phe arg ser leu glu cys thr cys val cys ser asn cys lys lys ser lys leu cys/ leu pro gln ile glu asn

, or a C- and/or N- terminally shortened sequence thereof, wherein R² is absent or is a polypeptide which can be cleaved *in vivo*; and

B) a polypeptide comprising the amino acid sequence:

R² asp val ser gln gly lys tyr ile his qln cys pro pro asn asn ser ile cys cys thr lys cys his lys gly thr tyr leu tyr asn asp cys pro gly pro gly gln asp thr asp cys arg glu cy\$ glu gly ser phe thr ala ser glu asn his leu ser glu hi\$ **CVS** leu lys lys met gly arg ser cys ser CVS arg vál gln glu ile ser ser Cys thr val asp arg asp thr val cys glu cys gly arg lys asn gln tyr arg his tyr trp ser phe gln phe leu leu gly asn *l*eu cys asn cys ser cys asn thr kal his leu ser Cys gln glu lys gln asn thr val cys thr his ala gly phe phe leu glu glu val cys arg asn Cys thr cys leu glu cys lys leu ser cys ser asn lys lys ser cys leu pro gln ile glu asn val lys gly thr glu asp ser thr gly thr

, of a C- and/or N- terminally shortened sequence thereof, wherein R² is absent or is a polypeptide which can be cleaved *in vivo*.

84. Polypeptide according to claim 83, wherein R² is a polypeptide comprising an amino acid sequence which can be cleaved *in vivo*.

85. Polypeptide according to claim 84, wherein R² is a polypeptide comprising the amino acid sequence :

TOSSO

gly leu thr asp leu leu leu leu val ser val pro pro leu glu leu leu val gly ile tyr pro ser gly val ile gly

; or a C- and/or N- terminally shortened sequence thereof.

- 86. Polypeptide according to claim 83, wherein said polypeptide is not associated with human urinary proteins.
- 87. A polypeptide having the ability to bind to TNF comprising an amino acid sequence as set forth in claim 83 with at least one intrasequence conservative amino acid substitution in the sequence of claim 83.
- 88. Polypeptide according to claim 87, wherein said polypeptide includes at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and at the carboxyl-terminus.
- 89. Polypeptide according to claim 88, wherein said polypeptide includes at least one additional amino acid at the amino-terminus and at the carboxyl-terminus.
- 90. Polypeptide according to claim 88, wherein said polypeptide includes at least one additional amino acid at the amino-terminus.
- 91. Polypeptide according to claim 90, wherein said polypeptide includes a methionine at the amino-terminus.
- 92. Polypeptide according to claim 88, wherein said polypeptide includes at least one additional amino acid at the carboxyl-terminus.
- 93. Polypeptide according to claim 87, wherein said polypeptide includes a methionine at the amino-terminus and said amino acid substitution is at a glycosylation site.

- 94. Polypeptide according to claim 87, wherein said amino acid substitution is at a glycosylation site.
- 95. A recombinant/polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, characterized in that the polypeptide is encoded by a nucleic acid which hybridizes with DNA complementary to the DNA defined in claim 83 under conditions of moderate stringency.
- 96. Polypeptide according to claim 83, wherein said polypeptide is selected from the group consisting of:
 - A) a polypeptide comprising the amino acid sequence:

asp ser val cys pro gln gly lys tyr ile his pro gln asn ile thr asn cys lys cys his lys gly thr tyr leu ser cys a/sp pro thr tyr asn cys pro gly gly gln asp asp cys arg glu cys ģlu ser gly ser phe thr ala ser glu asn his leu his /cys leu ser cys ser lys CVS lys glu met gly arg arg gln val glu ile thr ser ser cys val asp asp thr val arg gly cys arg lvs asn aln tyr his tyr trp **CYS** arg leu phe gln phe leu ser glu asn cys asn cys ser leu cys gly thr val his leu cys gln glu lys gln thr asn ser asn val cy\$ thr cys his ala gly phe phe leu arg glu asn glu CVS val thr ser Cys ser asn Cys lys lys ser leu glu cys lys le⁄u cys leu gln ile glu asn pro

, or a ϕ - and/or N- terminally shortened sequence thereof;

B) /a polypeptide comprising the amino acid sequence:

leu val pro his leu gly asp arg glu lys arg asp ser val pro cys pro gln gly lys tyr ile his gln asn asn ser ile cys thr lys cys his lys gly thr leu cys tyr tyr asn asp су\$ thr pro gly pro gly gln asp CVS glu glu asp arg Cys ser gly ser phe thr ala ser glu asn his leu arg his cys leµ ser cys ser lys Cys arg lys glu met gly gln val glu ilé thr val thr ser ser cys asp arg asp val cys gly cys arg lys asn gln tyr arg his tyr trp ser glu asn leu phe ģln. his phe asn ser leu leu asn gly thr val Cys **CYS** Cys leu his ser gln asn thr val thr cys gln glu lys cys cys

July Cont.

phe val glu glu cys ser ćys ser ala gly phe leu arg asn leu cys thr lys cys' leu asn cys lys lys ser leu glu pro ile gln glu asn

, or a C- and/or N- terminally shortened sequence thereof;

C) a polypeptide comprising the amino acid sequence:

val cys gln gly lys tyr ile his pro gln asn ser pro asp his' ile cys cys thr lys cys lys gly thr tyr leu asn ser gln thr tyr asn asp Cys pro gly pro gly asp asp CVS arg glu phe thr ala asn leu glu cys ser gly ser ser glu his his cys leu ser **CYS** ser lyş/ cys arg lys glu met gly arg thr gln glu ile ser ser **CYS** val asp thr val val asp arg gln lys asn tyr his trp ser glu **Cys** gly cys arg arg tyr asn leu phe gln cys phe asní **CYS** ser leu cys leu asn gly val his leu ser cys gľn glu lys gln asn thr val thr **CYS** his ala gly phe phe! leu glu asn glu CVS val thr cys arg glu thr lys ser cys ser asn cys lys lys ser leu cys leu gļú asn glu leu gln ile val lys gly thr asp ser cys pro gly thr thr

, or a C- and/or N- terminally shortened sequence thereof; and

D) a polypeptide comprising the amino acid sequence:

leu val pro hiş leu gly glu lys arg ser val asp arg asp cys pro gln gly lys tyr ile his pro gln asn asn ser ile ⁄lys thr his thr tyr leu **CYS** CVS **CYS** lys gly tyr asn asp thr cys pro gly pro gly gln asp asp **CYS** arg glu cys glu ser gly sęŕ phe thr ala ser glu asn his leu arg his cys çýs leu ser lys cys lys glu met gly gln val glu ser arg ile ser thr thr val gly ser cys val asp arg asp cys cys lys asn gln tyr his tyr trp ser glu asn leu phe arg arg gln phe leu his cyś asn cys ser leu cys asn gly thr val sér leu gln glu lys gln asn thr val cys thr cys his cys ala ģΙy phe glu val phe leu arg glu asn cys ser cys ser lys lys thr lys leu **CYS** ser leu glu cys **CYS** leu pro asn gln/ ile glu thr glu thr thr asn val lys gly asp ser gly

or a C- and/or N- terminally shortened sequence thereof.



- 97. Polypeptide according to claim 96, wherein said polypeptide includes at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and at the carboxyl-terminus.
- 98. Polypeptide according to claim 97, wherein said polypeptide includes at least one additional amino acid at the amino-terminus and at the carboxyl-terminus.
- 99. Polypeptide according to claim 97, wherein said polypeptide includes at least one additional amino acid at the amino-ten finus.
- 100. Polypeptide according to claim 99, wherein said polypeptide includes a methionine at the amino-terminus.
- 101. Polypeptide according to claim 97, wherein said polypeptide includes at least one additional amino acid at the carboxyl-terminus.
- Polypeptide according to claim 66, wherein said polypeptide is not associated with human urinary proteins.
- 103. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is selected from the group consisting of: :
 - A) a polypeptide comprising the amino acid sequence:

ser his met asp val cys pro gln gly lys tyr ile pro gln øer. asn asn ile cys cys thr lys cys his lys gly thr tyr ′asn asp leu cys pro pro gly gln asp thr tyr gly asp CVS arg glu cys glu ser gly ser phe thr ala ser glu asn his leu arg his **CYS** leu ser Cys ser lys Cys arg lys glu met gly gļń val glu ile ser thr val ser cys asp arg asp thr val ¢ys gly CVS arg lys asn gln tyr arg his tyr trp ser glu asn leu phe gln phe leu Cys asn cys ser Cys leu asn his gly thr val leu ser cys gln glu lys gln asn thr val thr cys his ala phe cys/ gly phe leu arg glu asn glu cys vaľ ser cys ser asn cys lys lys ser leu glu CVS thr lys leu cys leu ile glu pro gln asn

or a C- and/or N- terminally shortened sequence thereof;

89 E

- 15 -

ر الاس

B) a polypeptide comprising the amino acid sequence:

met	leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser/
val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	şer
ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr /	asn
asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glự	cys
glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	∕aŕg	his
cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly/	gln	val
glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	vaĺ	cys	gly
cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	∕glu	asn	leu
phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	_asņ∕	gly	thr	val
his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys
his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys
ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu
pro	gln	ile	glu	asn					•				

, or a C- and/or N- terminally shortened sequence thereof;

C) a polypeptide comprising the amino acid sequence:

met	asp	ser	val	cys	pro	gln	glý	lys	tyr	ile	his	pro	gln
asn	asn	ser	ile	cys	cys	thr	بربو √lys	cys	his	lys	gly	thr	tyr
asii	asii	301	110	Cys	Cys		/ iyo	•		iyo		CHII	tyi
leu	tyr	asn	asp	cys	pro	gly/	pro	gly	gln	asp	thr	asp	cys
arg	glu	cys	glu	ser	gly	şér	phe	thr	ala	ser	glu	asn	his
leu	arg	his	cys	leu	ser	/cys	ser	lys	cys	arg	lys	glu	met
gly	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr
val	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser
glu	asn	leu	phe	gln	/cys	phe	asn	cys	ser	leu	cys	leu	asn
gly	thr	val	his	leu/	ser	cys	gln	glu	lys	gln	asn	thr	val
cys	thr	cys	his	ạľa	gly	phe	phe	leu	arg	glu	asn	glu	cys
val	ser	cys	ser	/asn	cys	lys	lys	ser	leu	glu	cys	thr	lys
leu	cys	leu	pro/	gln	ile	glu	asn	val	lys	gly	thr	glu	asp
ser	gly	thr	thr										

, or a C- and/or,N- terminally shortened sequence thereof;

D) a polypeptide comprising the amino acid sequence:

met	leu/	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser
val	cy,ś	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser
ile	çýs	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn





pro gly pro gly gln asp thr **CYS** glu asp **CYS** asp arg **CVS** glu ser gly ser phe thr ala ser glu asn his leu arg his **CVS** leu Cys lys lys gln val ser ser cys arg glu met gly ⁄gly glu ile ser ser cys thr val asp arg asp thr val cys Cys arg lys asn gln tyr arg his tyr trp ser glu asn/ leu phe gln phe asn leu thr val cys cys ser cys leu asn gly his leu cys gln glu lys gln thr val cys thr ser asn **CYS** his ala gly phe phe leu arg glu asn glu cys val ser cys thr cys lys lys leu glu cys lys leu cys leu ser asn ser **s**er pro gln ile glu asn val lys gly thr glu asp gly thr thr

, or a C- and/or N- terminally shortened sequence thereof;

E) a polypeptide comprising the amino acid sequence:

thr val asp leu/ leu val met gly leu ser pro leu pro leu leu ile t√r ile leu leu glu leu val gly pro ser gly val his leu gly leu val pro gly asp ′arg glu lys arg asp ser val cys pro gln gly lys tyr ile, his pro gln asn asn ser ly's thr lys cys his thr leu asn ile **CYS** gly tyr tyr **CYS** asp cys pro gly pro gly gln asp thr asp **CYS** arg glu **CYS** ala/ glu ser gly ser phe thr ser glu asn his leu arg his çýs cys leu ser cys ser lys arg lys glu met gly gln val thr νal thr glu ile ser ser cys asp arg asp val cys gly cys arg lys asn gln tyr arg his tyr trp ser glu asn leu val phe gln asn cy's ser leu CVS leu asn gly thr **CYS** phe his leu ser cys gln ∕ģlu lys gln asn thr val cys thr cys leu his ala gly phe phe arg glu asn glu cys val ser cys lyş' ser thr ser asn cys lys leu glu cys lys leu cys leu gln ile glu asn pro

, or a C- and/or N- terminally shortened sequence thereof;

F) a polypeptide comprising the amino acid sequence:

met	gly	leu/	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	gļú	leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile
											arg		
											asn		
ile	cyş/	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn

E'st.



pro gly pro gly gln asp thr **CYS** arg glu asp **CYS** asp **CVS** glu ser gly ser phe thr ala ser glu asn his leu arg his val/ **CVS** leu ser lys lys met gly cys ser cys arg glu gln ile glu ser ser cys thr val asp arg asp thr val cys glý **CVS** arg lys asn gln tyr arg his tyr trp ser glu asn 1eu gln phe phe cys asn cys ser leu cys leu asn gly thr, val his leu gln glu gln thr val thr ser **CYS** lys asn CVS **CVS** his ala gly phe phe leu arg glu asn glu cys val ⁄ser **CYS** leu glu thr lys leu, leu ser asn **CYS** lys lys ser cys **CYS** pro gln ile glu asn val lys gly thr glu asp sér gly thr thr

, or a C- and/or N- terminally shortened sequence thereof;

G) a polypeptide comprising the amino acid sequence?

gly leu thr val asp leu 1eu leu leu val met ser pro pro leu glu leu leu val gly ile tyr, ile leu pro ser gly val val gln lyś ile his gly asp ser cys pro gly tyr pro gln asn asn ser ile cys cys thr lys cys his lys gly thr tyr pro/ gly thr leu tyr asn asp **CYS** pro gly gln asp asp cys phe thr his arg glu cys glu ser gly ser ala ser glu asn ⁄ser leu arg his **CVS** leu ser cys lys **CVS** arg lys glu met gly gln val glu ile ser ser cys thr val asp arg asp thr lys as'n his gly cys arg gln tyr arg tyr trp ser val cys phe. glu asn leu phe gln cys asn cys ser leu cys leu asn leu ser glu gln asn thr val gly thr val his cys gln lys phe cys thr cys his ala gly phe leu arg glu asn glu cys val ser **CYS** ser asn **c**ys lys lys ser leu glu cys thr lys 'ile leu cys leu pro gln glu asn

, or a C- and/or N- terminally shortened sequence thereof;

H) a polypeptide comprising the amino acid sequence:

met	gly	leu	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	glu /	/leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile
	asp												
	asn												
leu	tyr	∕ásn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys
arg	glu 🖊	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his

Cont.

Authorized to the control of the control of

leu arg his cys leu ser **CVS** ser lys **CVS** arq lys alu met gln val glu ile thr gly ser ser **CYS** val asp arg asp thr. val gly lys sér cys cys arg asn gln tyr his trp arg tyr glu leu phe gln phe ∕asn asn cys asn CVS ser leu Cys leu his leu gly thr val ser CVS gln glu lvs gln asn thr val cys thr cys his ala gly phe phe leu glu asn glyí cys arg val ser CVS ser asn CVS lys lys ser leu glu cys thr lys gln leu cys leu pro ile glu asn val lys gly thr glu asp thr thr ser gly

, or a C- and/or N- terminally shortened sequence thereof; and

I) a polypeptide comprising the amino acid sequence:

leu leu met leu thr val asp leu/ leu val gly ser pro pro рю leu leu glu leu leu val gly ile tyr ile ser gly val arg ģlu leu val his leu gly lys gly pro asp arg asp ser gln gly ile his val cys pro lys tyr pro gln asn asn ser ile thr lys **Cys** his gly thr tyr cys **CYS** lys leu tvr asn asp cys pro gly pro gly gln asp thr asp **CYS** arg glu cys glu phe thr ser glu his his gly ser ala asn leu ser arg cys lys cys arg' lys glu gly gln val leu ser cys ser met val aśp glu ile thr thr val gly ser ser **CVS** arq asp cys his cys gln trp glu asn leu arg lys asn tyr arg tyr ser phe qln phe asn CVS ser leu CVS leu asn gly thr val cys ly,s thr his leu ser **CYS** gln glu gln asn val **CYS** thr **CYS** phe ala leu glu val his gly phe árg glu asn **CYS** ser CVS ser leu thr lys leu ser asn **CYS** lys lys glu CVS leu cys val/ ile glu lvs qlu thr pro gln asn gly thr asp ser gly leu thr leu leu pro val ile phe phe gly leu leu val cys leu leu leu phe ∕ile gly leu met tyr tyr gln arg ser arq leu thr trp lys ser lys tyr ser ile val cys gly lys ser gly glu thr thr glu lys glu leu glu gly thr lys pro pro pro ser phe thr thr leu ala pro asn ser pro pro gly phe thr gly phe ser pro val pro ser ser thr phe thr pro leu ser thr tyr thr gly Cys pro asn phe ala ser ser pro asp ala qlu val ala tyr qln qly ala pro arq arg pro pro asp ala pro ile leu thr ala leu ala ser asp pro ile pro asn gln lys his lys pro leu trp glu asp ser ala pro gln ser leu thr ala thr leu val asp asp asp pro tyr ala val glu pro asn val pró leu lys alu phe val leu arq trp arg arg

E to the factor of the factor

Dury S

gly leu ser asp his glu ile asp arg leu.⊸ glu leu qln asn gln leu glu ser met gly arg cys arg ala tyr_ leu ala thr trp thr glu ala thr leu arg arg arg pro ara arg glu leu leu gly arg val leu arg met asp leu leu gly **CYS** leu 1eu 1 cys glu ile glu ala asp glu gly pro ala ala leu pro Teu pro ala pro ser arg

, or a C- and/or N- terminally shortened sequence thereof.

104. Polypeptide according to claim 103, wherein said polypeptide includes at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and at the carboxyl-terminus.

105. Polypeptide according to claim 104, wherein said polypeptide includes at least one additional amino acid/at the earboxyl-terminus.

106. Polypeptide according to claim 103, wherein said polypeptide is not associated with human urinary proteins.--

REMARKS

Claims 40 to 48 and 54 to 66 have been canceled without prejudice or disclaimer.

Claims 27, 49, 67, and 68 have been amended to change their dependency. Claims 69 to 106 have been added. Thus, claims 24, 27 to 39, 49 to 53, 67, 68, and 69 to 106 are pending.

The amendments and the cancellation of claims have not been made in response to a rejection or in acquiescence to a rejection. The amendments have been made to even more clearly recite the applicants' inventions.

Solely to expedite prosecution, applicants have amended and canceled claims such that the term "variant" is not included in the claims. The terms "variant" (other than "degenerate variants") was not included in the claims as previously examined, and thus, there

